

# Pre- versus post-dilution haemofiltration: a prospective randomised cross-over study

<b>Submission date</b> 05/07/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 06/07/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 14/09/2009	<b>Condition category</b> Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mrs Anne-Cornelie de Pont

**Contact details**  
Academic Medical Center  
Meibergdreef 9  
Amsterdam  
Netherlands  
1105 AZ  
+31 (0)20 5669111 tracer 59229  
a.c.depont@amc.uva.nl

## Additional identifiers

## Study information

**Scientific Title**

**Acronym**  
PREPOST

**Study objectives**

Predilution prolongs extracorporeal circuit survival time during continuous venovenous hemofiltration, due to a decrease in platelet activation and thrombin generation.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Acute renal failure

**Interventions**

Continuous venovenous haemofiltration, predilution versus postdilution

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Extracorporeal circuit survival time

**Key secondary outcome(s)**

Platelet activation, thrombin generation, urea clearance

**Completion date**

01/01/2002

**Eligibility**

**Key inclusion criteria**

Eight critically ill patients with an indication for renal replacement therapy

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

Recent bleeding, treatment with aspirin within one week before inclusion or with therapeutic doses of unfractionated or low molecular weight heparin within 12 hours before inclusion or results of routine coagulation tests such as prothrombin time (PT) and activated partial thromboplastin time (APTT) exceeding twice the upper limit of normal

**Date of first enrolment**

01/12/2000

**Date of final enrolment**

01/01/2002

**Locations****Countries of recruitment**

Netherlands

**Study participating centre**

**Academic Medical Center**

Amsterdam

Netherlands

1105 AZ

**Sponsor information****Organisation**

Academic Medical Centre (Netherlands)

**ROR**

<https://ror.org/03t4gr691>

**Funder(s)****Funder type**

Hospital/treatment centre

**Funder Name**

Internally funded (Netherlands)

**Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration